Literature DB >> 19669247

The saga of entecavir.

Ching-Lung Lai1, Man-Fung Yuen.   

Abstract

Year:  2009        PMID： 19669247      PMCID： PMC2748373          DOI： 10.1007/s12072-009-9138-x

Source DB:  PubMed          Journal:  Hepatol Int        ISSN： 1936-0533            Impact factor:   6.047


× No keyword cloud information.
  28 in total

1.  Chronic hepatitis B.

Authors:  Anna S F Lok; Brian J McMahon
Journal:  Hepatology       Date:  2007-02       Impact factor: 17.425

2.  Chronic hepatitis B--new goals, new treatment.

Authors:  Ching-Lung Lai; Man-Fung Yuen
Journal:  N Engl J Med       Date:  2008-12-04       Impact factor: 91.245

Review 3.  Hepatitis B virus infection.

Authors:  Jules L Dienstag
Journal:  N Engl J Med       Date:  2008-10-02       Impact factor: 91.245

4.  The polymerase L528M mutation cooperates with nucleotide binding-site mutations, increasing hepatitis B virus replication and drug resistance.

Authors:  S K Ono; N Kato; Y Shiratori; J Kato; T Goto; R F Schinazi; F J Carrilho; M Omata
Journal:  J Clin Invest       Date:  2001-02       Impact factor: 14.808

5.  Entecavir is superior to lamivudine in reducing hepatitis B virus DNA in patients with chronic hepatitis B infection.

Authors:  Ching-Lung Lai; Mohamed Rosmawati; Judy Lao; Hans Van Vlierberghe; Frank H Anderson; Neal Thomas; Deborah Dehertogh
Journal:  Gastroenterology       Date:  2002-12       Impact factor: 22.682

6.  Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B.

Authors:  Patrick Marcellin; E Jenny Heathcote; Maria Buti; Ed Gane; Robert A de Man; Zahary Krastev; George Germanidis; Sam S Lee; Robert Flisiak; Kelly Kaita; Michael Manns; Iskren Kotzev; Konstantin Tchernev; Peter Buggisch; Frank Weilert; Oya Ovung Kurdas; Mitchell L Shiffman; Huy Trinh; Mary Kay Washington; Jeff Sorbel; Jane Anderson; Andrea Snow-Lampart; Elsa Mondou; Joe Quinn; Franck Rousseau
Journal:  N Engl J Med       Date:  2008-12-04       Impact factor: 91.245

7.  Lamivudine for patients with chronic hepatitis B and advanced liver disease.

Authors:  Yun-Fan Liaw; Joseph J Y Sung; Wan Cheng Chow; Geoffrey Farrell; Cha-Ze Lee; Hon Yuen; Tawesak Tanwandee; Qi-Min Tao; Kelly Shue; Oliver N Keene; Jonathan S Dixon; D Fraser Gray; Jan Sabbat
Journal:  N Engl J Med       Date:  2004-10-07       Impact factor: 91.245

8.  Cost effectiveness of entecavir versus lamivudine with adefovir salvage in HBeAg-positive chronic hepatitis B.

Authors:  David L Veenstra; Sean D Sullivan; Lauren Clarke; Uche H Iloeje; Eskinder Tafesse; Adrian Di Bisceglie; Kris V Kowdley; Robert G Gish
Journal:  Pharmacoeconomics       Date:  2007       Impact factor: 4.981

9.  Early hepatitis B virus DNA reduction in hepatitis B e antigen-positive patients with chronic hepatitis B: A randomized international study of entecavir versus adefovir.

Authors:  Nancy Leung; Cheng-Yuan Peng; Hie-Won Hann; Jose Sollano; Judy Lao-Tan; Chao-Wei Hsu; Laurentius Lesmana; Man-Fung Yuen; Lennox Jeffers; Morris Sherman; Albert Min; Kimberly Mencarini; Ulysses Diva; Anne Cross; Richard Wilber; Juan Lopez-Talavera
Journal:  Hepatology       Date:  2009-01       Impact factor: 17.425

10.  The natural history and treatment of chronic hepatitis B: a critical evaluation of standard treatment criteria and end points.

Authors:  Ching-Lung Lai; Man-Fung Yuen
Journal:  Ann Intern Med       Date:  2007-07-03       Impact factor: 25.391
View more
  1 in total

1.  Nephrotoxicity caused by oral antiviral agents in patients with chronic hepatitis B treated in a hospital for tropical diseases in Thailand.

Authors:  Aung Myint Thu; Kittiyod Poovorawan; Chatporn Kittitrakul; Apichart Nontprasert; Natthida Sriboonvorakul; Weerapong Phumratanaprapin; Pisit Tangkijvanich; Wattana Leowattana; Polrat Wilairatana
Journal:  BMC Pharmacol Toxicol       Date:  2015-12-14       Impact factor: 2.483
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.